| Autor: |
Tharmalingham, H., Hoskin, P.J. |
| Zdroj: |
Technical Innovations & Patient Support in Radiation Oncology; March 2017, Vol. 1 Issue: 1 p13-15, 3p |
| Abstrakt: |
It is clear from surgical series that there are selected patients presenting with localised metastatic disease who can be cured by radical ablation of the metastasis. To date this has been limited to surgical resection but the evolution of stereotactic ablative body radiotherapy (SABR) has opened new opportunities. Hypofractionated radiation delivery in 1 to 5 fractions can achieve durable local control with low toxicity. The focus is now to develop robust biomarkers so that those with true oligometastatic and thereby potentially curable disease can be selected for this approach. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
